Long-Term Follow Up of Patients Receiving Novel Gene Therapy for SMA Type ILong-Term Follow Up of Patients Receiving Novel Gene Therapy for SMA Type I https://pediatricsnationwide.org/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150 Abbie Roth Abbie Roth https://pediatricsnationwide.org/wp-content/uploads/2021/02/062019ds5821_abbie-profile-new.jpg
- April 19, 2019
- Abbie Roth
Spinal muscular atrophy type 1 (SMA1) is a rare neuromuscular disease in which 75 percent of affected children die or require permanent ventilation by 13.6 months. Researchers recently published the long-term outcomes of patients who received the investigational drug AVXS-101 – an adeno-associated virus serotype 9 mediated gene replacement therapy.
Twelve children aged 1 to 8 months were treated and followed for 24 months. Longer-term follow up results are included as available for motor milestones.
Notably, for motor milestones, the patient who was the oldest at treatment achieved fewer milestones than those treated at younger ages.
Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbours O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatric Pulmonology. 2019;54:179-185.
Image credits: Adobe Stock (header); Nationwide Children’s (infographic)
About the author
You might also like
Long-Term Pulmonary Symptoms Following COVID-19 Infection in ChildrenLong-Term Pulmonary Symptoms Following COVID-19 Infection in Children https://pediatricsnationwide.org/wp-content/uploads/2022/08/InPractice_Brief_Long-Term-Pulmonary-Symptoms-Follow-COVID-19-Infection-in-Children-1024x683.jpg 1024 683 Mary Bates, PhD Mary Bates, PhD https://secure.gravatar.com/avatar/c6233ca2b7754ab7c4c820e14eb518c8?s=96&d=mm&r=g
Featured Researcher — Allison Bradbury, MS, PhDFeatured Researcher — Allison Bradbury, MS, PhD https://pediatricsnationwide.org/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150 Katie Brind'Amour, PhD, MS, CHES Katie Brind'Amour, PhD, MS, CHES https://pediatricsnationwide.org/wp-content/uploads/2021/03/Katie-B-portrait.gif
A Single-Dose Cancer Immunotherapy via Gene TransferA Single-Dose Cancer Immunotherapy via Gene Transfer https://pediatricsnationwide.org/wp-content/uploads/2022/07/AdobeStock_134232290-DNA-header-1024x575-1.gif 1024 575 Mary Bates, PhD Mary Bates, PhD https://secure.gravatar.com/avatar/c6233ca2b7754ab7c4c820e14eb518c8?s=96&d=mm&r=g